

CORRIGENDUM

A novel arsenical has antitumor activity toward As₂O₃-resistant and MRP1/ABCC1-overexpressing cell lines

Z Diaz, KK Mann, S Marcoux, M Kourelis, M Colombo, PB Komarnitsky and WH Miller Jr

Leukemia (2009) 23, 431; doi:10.1038/leu.2008.328

Correction to: *Leukemia* (2008) 22, 1853–1863; doi:10.1038/leu.2008.194

The authors apologize for any inconvenience caused.

Since the publication of this paper, the authors have noticed errors in Figure 1a. The correct Figure 1a is shown here.




Figure 1 Darinaparsin (DAR) is more potent than As₂O₃ at inducing growth inhibition and apoptosis in NB4, AR2, IM9 and CCRF-CEM cells. Cells were treated with DAR or As₂O₃ as indicated for 48 h. (a) Cell viability was evaluated using Trypan blue exclusion. Each bar represents an average of three independent samples, and standard deviation bars are shown. Asterisks indicate significant differences from As₂O₃-treated cells (*P=0.05; **P=0.01; ***P=0.001).